196597-85-0 Usage
Description
(S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide is a synthetic compound characterized by its complex molecular structure. It is an amide derivative, featuring a propionamide group, an allyloxy group, and a bromo group. Additionally, it contains an inden-1-yl ring, which is a bicyclic aromatic structure. (S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide holds potential in the fields of medicinal chemistry and drug discovery due to its unique structural features. Given its complexity and specific functional groups, it is essential to handle and store this chemical with care to prevent degradation or unwanted chemical reactions that could affect its properties.
Uses
Used in Medicinal Chemistry:
(S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide is used as a potential candidate in medicinal chemistry for its unique molecular structure. The presence of various functional groups, such as the allyloxy and bromo groups, along with the propionamide and inden-1-yl ring, may contribute to its biological activity and make it a promising compound for further research and development.
Used in Drug Discovery:
In the field of drug discovery, (S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide is utilized as a starting point for the development of new pharmaceuticals. Its complex structure and specific functional groups may offer novel mechanisms of action or interactions with biological targets, leading to the discovery of new therapeutic agents.
Used in Pharmaceutical Research:
(S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide is employed in pharmaceutical research as a compound with potential applications in the development of new drugs. Its unique structure and functional groups may provide insights into novel drug targets or pathways, contributing to the advancement of medical treatments.
Used in Chemical Synthesis:
In the chemical synthesis industry, (S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide may be used as a building block or intermediate in the synthesis of more complex molecules. Its specific functional groups and structural features can be exploited to create a variety of new compounds with potential applications in various fields, including pharmaceuticals, materials science, and agrochemicals.
Used in Material Science:
(S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide is utilized in material science for its potential to contribute to the development of new materials with unique properties. (S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide's structural features and functional groups may be harnessed to create materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity.
Used in Agrochemicals:
In the agrochemical industry, (S)-N-[2-(6-allyloxy-5-bromo-2,3-dihydro-1H-inden-1-yl)ethyl]propionamide may be explored for its potential applications in the development of new pesticides, herbicides, or other agricultural chemicals. Its unique structure and functional groups could provide novel modes of action or target specific pests or weeds, leading to more effective and environmentally friendly solutions for agriculture.
Check Digit Verification of cas no
The CAS Registry Mumber 196597-85-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,5,9 and 7 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 196597-85:
(8*1)+(7*9)+(6*6)+(5*5)+(4*9)+(3*7)+(2*8)+(1*5)=210
210 % 10 = 0
So 196597-85-0 is a valid CAS Registry Number.
196597-85-0Relevant articles and documents
Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists
Uchikawa, Osamu,Fukatsu, Kohji,Tokunoh, Ryosuke,Kawada, Mitsuru,Matsumoto, Kiyoharu,Imai, Yumi,Hinuma, Shuji,Kato, Koki,Nishikawa, Hisao,Hirai, Keisuke,Miyamoto, Masaomi,Ohkawa, Shigenori
, p. 4222 - 4239 (2007/10/03)
To develop a new therapeutic agent for sleep disorders, we synthesized a novel series of tricyclic indan derivatives and evaluated them for their binding affinity to melatonin receptors. In our previous paper, we proposed a conformation of the methoxy group favorable for the binding of the MT1 receptor. To fix the methoxy group in an active conformation, we decided to synthesize conformationally restricted tricyclic indan analogues with the oxygen atom in the 6-position incorporated into a furan, 1,3-dioxane, oxazole, pyran, morpholine, or 1,4-dioxane ring system. Among these compounds, indeno[5,4-b]furan analogues were found to be the most potent and selective MT1 receptor ligands and to have superior metabolic stability. The optimization of substituents led to (S)-(-)-22b, which showed very strong affinity for human MT1 (Ki = 0.014 nM), but no significant affinity for hamster MT3 (Ki = 2600 nM) or other neurotransmitter receptors. The pharmacological effects of (S)-(-)-22b were studied in experimental animals, and it was found that a dose of 0.1 mg/kg, po promoted a sleep in freely moving cats, as demonstrated by a decrease in wakefulness and increases in slow wave sleep and rapid eye movement sleep, which lasted for 6 h after administration. Melatonin (1 mg/kg, po) also had a sleep-promoting effect, though it lasted only 2 h. A new chiral method for the synthesis of (S)-(-)-22b starting from 60, which was prepared from 59 employing asymmetric hydrogenation with the (S)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl-Ru complex, was developed. (S)-(-)-22b (TAK-375) is currently under clinical trial for the treatment of insomnia and circadian rhythm disorders.
Tricyclic compounds, their production and use
-
, (2008/06/13)
A compound of the formula: STR1 wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.
